Cervical Screening Clinical Practice Guideline: an adaptation
of S3- Leitlinie Prävention des Zervixkarzinoms

a 2022

Cervical Screening Clinical Practice Guideline: an adaptation of S3- Leitlinie Prävention des Zervixkarzinoms

VRBOVÁ, Tereza, Vladimír DVOŘÁK, Radovan TURYNA, Jaroslava DUŠKOVÁ, Markéta TRNKOVÁ et. al.

Základní údaje

Originální název

Cervical Screening Clinical Practice Guideline: an adaptation of S3- Leitlinie Prävention des Zervixkarzinoms

Autoři

VRBOVÁ, Tereza, Vladimír DVOŘÁK, Radovan TURYNA, Jaroslava DUŠKOVÁ, Markéta TRNKOVÁ, Jiří ONDRUŠ a Miloslav KLUGAR

Vydání

GIN 2022, Toronto, 2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Kanada

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Cervical Screening; Clinical Practice Guideline;

Změněno: 10. 10. 2022 09:21, Mgr. Bc. Alena Langaufová, Ph.D.

Anotace

V originále

Background The determining cause of cervical carcinoma is Human Papilloma Virus infection. The aim of cervical screening is to reduce mortality and morbidity of cervical carcinoma by early diagnoses and treatment. Organized screening has proved reduced incidence of malignant tumours and mortality of cervical carcinoma. However, there is an ongoing discussion about lengths of screening intervals, age in patients and tests in order to identify high-grade lesions. Objective This project, a part of the Czech National Clinical Practice Guideline (CPG) Project, aimed to develop a trustworthy CPG, which would help diagnose cervical carcinoma in time, considering different tests, organizational structures, treatment management and screening participation. The CPG aims to decrease mid-term and long-term incidence and mortality in patients with cervical lesions and improve their quality of life. Methods & future prospects A systematic search yielded 43 (inter)nationl CPGs, which were compared against including and excluding criteria and assessed by AGREEII tool. The working group has adapted German guideline “Prävention des Zervixkarzinoms”. Most of the recommendations were adopted and contextualized, only legal distinctions were considered. There are international differences regarding the lowest and highest ages for organised cervical screening, there is a lack of studies in patients over 65. In the Czech Republic, women are granted prevention gynaecological examination (and opportunity screening) from the age of 15, women between 25 and 65 are included in organised screening. The working group of the CPG suggest a nationwide 3-arm-study regarding screening intervals for a transitive period, before any change in legislation is suggested.

Citovat

VRBOVÁ, Tereza, Vladimír DVOŘÁK, Radovan TURYNA, Jaroslava DUŠKOVÁ, Markéta TRNKOVÁ, Jiří ONDRUŠ a Miloslav KLUGAR. Cervical Screening Clinical Practice Guideline: an adaptation of S3- Leitlinie Prävention des Zervixkarzinoms. In GIN 2022, Toronto. 2022.

@proceedings{2223802,
   author = {Vrbová, Tereza and Dvořák, Vladimír and Turyna, Radovan and Dušková, Jaroslava and Trnková, Markéta and Ondruš, Jiří and Klugar, Miloslav},
   booktitle = {GIN 2022, Toronto},
   keywords = {Cervical Screening; Clinical Practice Guideline;},
   language = {eng},
   title = {Cervical Screening Clinical Practice Guideline: an adaptation of S3- Leitlinie Prävention des Zervixkarzinoms},
   url = {http://icsevents.eventsair.com/gin2022/},
   year = {2022}
}

TY  - CONF
ID  - 2223802
AU  - Vrbová, Tereza - Dvořák, Vladimír - Turyna, Radovan - Dušková, Jaroslava - Trnková, Markéta - Ondruš, Jiří - Klugar, Miloslav
PY  - 2022
TI  - Cervical Screening Clinical Practice Guideline: an adaptation of S3- Leitlinie Prävention des Zervixkarzinoms
KW  - Cervical Screening
KW  - Clinical Practice Guideline;
UR  - http://icsevents.eventsair.com/gin2022/
N2  - Background The determining cause of cervical carcinoma is Human Papilloma Virus infection. The aim of cervical screening is to reduce mortality and morbidity of cervical carcinoma by early diagnoses and treatment. Organized screening has proved reduced incidence of malignant tumours and mortality of cervical carcinoma. However, there is an ongoing discussion about lengths of screening intervals, age in patients and tests in order to identify high-grade lesions. Objective This project, a part of the Czech National Clinical Practice Guideline (CPG) Project, aimed to develop a trustworthy CPG, which would help diagnose cervical carcinoma in time, considering different tests, organizational structures, treatment management and screening participation. The CPG aims to decrease mid-term and long-term incidence and mortality in patients with cervical lesions and improve their quality of life. Methods & future prospects A systematic search yielded 43 (inter)nationl CPGs, which were compared against including and excluding criteria and assessed by AGREEII tool. The working group has adapted German guideline “Prävention des Zervixkarzinoms”. Most of the recommendations were adopted and contextualized, only legal distinctions were considered. There are international differences regarding the lowest and highest ages for organised cervical screening, there is a lack of studies in patients over 65. In the Czech Republic, women are granted prevention gynaecological examination (and opportunity screening) from the age of 15, women between 25 and 65 are included in organised screening. The working group of the CPG suggest a nationwide 3-arm-study regarding screening intervals for a transitive period, before any change in legislation is suggested.
ER  -

Podrobný výpis o publikaci